| Literature DB >> 30925798 |
Amine Allaoui1, Sonia Gascón2, Souhila Benomar3, Javier Quero4, Jesús Osada5, Moncef Nasri6, María Jesús Rodríguez-Yoldi7, Ahmed Boualga8.
Abstract
The application of plant extracts for therapeutic purposes has been used in traditional medicine since the plants are a source of a great variety of chemical compounds that possess biological activity. Actually, the effect of these extracts on diseases such as cancer is being widely studied. Colorectal adenocarcinoma is one of the main causes of cancer related to death and the second most prevalent carcinoma in Western countries. The aim of this work is to study the possible effect of two fenugreek (Trigonella foenum graecum) protein hydrolysates on treatment and progression of colorectal cancer. Fenugreek proteins from seeds were hydrolysed by using two enzymes separately, which are named Purafect and Esperase, and were then tested on differentiated and undifferentiated human colonic adenocarcinoma Caco2/TC7 cells. Both hydrolysates did not affect the growth of differentiated cells, while they caused a decrease in undifferentiated cell proliferation by early apoptosis and cell cycle arrest in phase G1. This was triggered by a mitochondrial membrane permeabilization, cytochrome C release to cytoplasm, and caspase-3 activation. In addition, the hydrolysates of fenugreek proteins displayed antioxidant activity since they reduce the intracellular levels of ROS. These findings suggest that fenugreek protein hydrolysates could be used as nutraceutical molecules in colorectal cancer treatment.Entities:
Keywords: Caco2 cells; antioxidant; antiproliferative; apoptosis; fenugreek; protein hydrolysate
Mesh:
Substances:
Year: 2019 PMID: 30925798 PMCID: PMC6521099 DOI: 10.3390/nu11040724
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Kinetic of fenugreek proteins hydrolysis. E/S ratio= 5 U/mg proteins. EFPH: Esperase-fenugreek proteins hydrolysate. PFPH: Purafect-fenugreek proteins hydrolysate.
Chemical composition of fenugreek protein hydrolysates.
| PFPH | EFPH | |
|---|---|---|
| (%) | (%) | |
| Proteins | 89.9 ± 0.2 | 92.3 ± 0.5 * |
| HAA | 49.4 | 49.0 |
| AAA | 16.8 | 17.2 |
| PCAA | 12.2 | 12.5 |
| Lipids | 2.8 ± 0.2 | 3.3 ± 0.4 * |
| Total fiber | 3.0 ± 0.1 | 2.0 ± 0.1 * |
| Carbohydrates # | 1.5 | ˂1 |
| Moisture | 1.0 ± 0.1 | 1.1 ± 0.1 |
| Ash | 1.8 ± 0.2 | 1.3 ± 0.3 |
| Mineral composition | ||
| Potassium (mg/100 g) | 986 ± 5 | 1001 ± 1 * |
| Phosphorus (µg/g) | 1933 ± 7 | 1927 ± 11 |
| Sulphide (µg/g) | 1128 ± 5 | 1268 ± 48 * |
| Magnesium (µg/g) | 1013 ± 4 | 985 ± 9 * |
| Calcium (µg/g) | 636 ± 2 | 502 ± 14 * |
| Sodium (µg/g) | 122 ± 4 | 110 ± 3 * |
| Selenium (µg/kg) | 53 ± 1 | 52 ± 1 |
PFPH: Purafect fenugreek proteins hydrolysate. EFPH: Esperase fenugreek proteins hydrolysate. HAA: hydrophobic amino acids (Ala, Val, Ile, Leu, Tyr, Phe, Trp, Pro, Met, and Cys). AAA: aromatic amino acids (Phe, Tyr, Trp). PCAA: positively charged amino acids (Arg, His, Lys). Results are presented as mean ± SD (n = 3). Superscripted (*) means within a row are significantly different (p ≤ 0.05). #: Calculated by difference.
Figure 2Relative viability of undifferentiated ((A): 24 h, 48 h, and 72 h) and differentiated Caco2/TC7 cells (B) treated (24 h) or not with fenugreek proteins hydrolysates. Data are presented as mean ± SD. The experiment was done in triplicate (each performed with six determinations). Superscripted (*) means are significantly different (p ≤ 0.05) compared to their respective control. Control: Untreated cells. PFPH: Purafect fenugreek proteins hydrolysate. EFPH: Esperase fenugreek proteins hydrolysate. The hydrolysates were used at a final concentration of 1 mg/mL.
Figure 3Effect of treating undifferentiated Caco2/TC7 cells with fenugreek proteins hydrolysates (24 h) on apoptosis. (a) Representative histogram of cytometry analysis. (b) Cell death process repartition. Data are presented as mean ± SD. The experiment was done in duplicate. Superscripted (*) means are significantly different (p ≤ 0.05) when compared to their respective control. Control: Untreated cells. PFPH: Purafect fenugreek proteins hydrolysate. EFPH: Esperase fenugreek proteins hydrolysate. The hydrolysates were used at a final concentration of 1 mg/mL.
Figure 4Cell cycle repartition of undifferentiated Caco2/TC7 treated (24 h) or not with fenugreek proteins hydrolysates. (a): a representative cells cycle histogram. (b): G1, S, and G2 phases percentage distribution. Data are presented as mean ± SD. The experiment was done in duplicate. Superscripted (*) means are significantly different (p ≤ 0.05) when compared to their respective control. Control: Untreated cells. PFPH: Purafect fenugreek proteins hydrolysate. EFPH: Esperase fenugreek proteins hydrolysate. The hydrolysates were used at a final concentration of 1 mg/mL.
Percentage of Caco2/CT7 cells with a positive mitochondrial membrane potential. Cells with mitochondrial cytochrome C and active caspase-3, quantified by flow cytometry in response to fenugreek proteins hydrolysates treatment (24 h).
| Number of Cells (/100 Cells) | Control | PFPH | EFPH |
|---|---|---|---|
| Cells with positive MMP | 28.7 ± 10.9 | 69.2 ± 11.4 * | 70.4 ± 4.1 * |
| Cells with mitochondrial cytochrome C | 90.7 ± 1.6 | 71.3 ± 1.2 * | 61.0 ± 9.8 * |
| Cells with active caspase-3 | 1.4 ± 0.0 | 33.3 ± 4.3 * | 18.5 ± 3.8 * |
Data are presented as mean ± SD. The experiment was done in duplicate. Superscripted (*) means within a row are significantly different (p ≤ 0.05) when compared to their respective control. Control: untreated cells. PFPH: Purafect fenugreek proteins hydrolysate. EFPH: Esperase fenugreek proteins hydrolysate. The hydrolysates were used at a final concentration of 1 mg/mL. MMP: mitochondrial membrane potential.
Figure 5Relative reactive oxygen species levels in undifferentiated Caco2/TC7 cells treated (24 h) or not with fenugreek proteins hydrolysates. Data are presented as mean ± SD. The experiment was done in triplicate (each performed with six determinations). Superscripted (*) means are significantly different (p ≤ 0.05) compared to their respective control. Control: Untreated cells. PFPH: Purafect fenugreek proteins hydrolysate. EFPH: Esperase fenugreek proteins hydrolysate. The hydrolysates were used at a final concentration of 1 mg/mL.
Figure 6Relative thioredoxin reductase activity in undifferentiated Caco2/TC7 cells treated (24 h) or not with fenugreek proteins hydrolysates. Data are presented as mean ± SD. The experiment was done in duplicate (each performed with six determinations). Superscripted (*) means are significantly different (p ≤ 0.05) compared to their respective control. Control: Untreated cells. PFPH: Purafect fenugreek proteins hydrolysate. EFPH: Esperase fenugreek proteins hydrolysate. The hydrolysates were used at a final concentration of 1 mg/mL.